{
    "clinical_study": {
        "@rank": "166699", 
        "brief_summary": {
            "textblock": "To evaluate short-term and long-term safety and efficacy of intravenous cidofovir (HPMPC)\n      for treatment of small peripheral cytomegalovirus (CMV) retinitis lesions. To provide data\n      on the relative safety and efficacy of 2 doses of HPMPC as maintenance regimens."
        }, 
        "brief_title": "HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol", 
        "completion_date": {
            "#text": "April 1996", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "In Stage 1, up to 30 patients are randomized to either observation with deferral of\n      treatment until the retinitis progresses (observation group), or to intravenous HPMPC at the\n      higher dose for two consecutive weekly induction doses, followed by the lower dose every\n      other week for maintenance. In Stage 2, up to 70 patients are randomized to observation or\n      to HPMPC at the higher dose for two consecutive weekly induction doses followed by either\n      dose every other week for maintenance, for a total of three treatment groups. Concomitant\n      saline hydration and probenecid are administered to patients receiving HPMPC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Oral trimethoprim/sulfamethoxazole.\n\n          -  Aerosolized pentamidine.\n\n          -  Dapsone.\n\n          -  Fluconazole.\n\n          -  Ketoconazole.\n\n          -  Itraconazole.\n\n          -  Rifabutin.\n\n          -  Filgrastim (G-CSF).\n\n          -  Antiretroviral agents.\n\n        Patients must have:\n\n          -  AIDS by CDC criteria.\n\n          -  CMV retinitis as determined by a SOCA-certified ophthalmologist, with lesion size,\n             location, and severity as specified in the Disease Status field.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prophylaxis with anti-CMV agents.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Ongoing therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune\n             immunoglobulin, or other investigational agents with anti-CMV activity.\n\n          -  Therapy with nephrotoxic drugs, including amphotericin B, aminoglycoside antibiotics,\n             vidarabine, and intravenous pentamidine.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of renal disease or renal dialysis.\n\n          -  History of clinically significant cardiac disease, including symptoms of ischemia,\n             congestive heart failure, or arrhythmia.\n\n          -  History of clinically significant probenecid allergy.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune\n             immunoglobulin, or other investigational agents with anti-CMV activity.\n\n          -  Therapy with nephrotoxic drugs within the past 7 days, including amphotericin B,\n             aminoglycoside antibiotics, vidarabine, and intravenous pentamidine.\n\n        Drug or alcohol abuse sufficient to hinder compliance with study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000799", 
            "org_study_id": "ACTG 281", 
            "secondary_id": [
                "GS-93-105", 
                "FDA 231A"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "Cidofovir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Probenecid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Probenecid", 
                "Cidofovir"
            ]
        }, 
        "keyword": [
            "Retinitis", 
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents", 
            "cidofovir"
        ], 
        "lastchanged_date": "October 31, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "920930946"
                    }, 
                    "name": "UCSD - Shiley Eye Ctr / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "900957003"
                    }, 
                    "name": "UCLA - Jules Stein Eye Institute / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "UCSF - San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "212879217"
                    }, 
                    "name": "Johns Hopkins Hosp / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York Univ Med Ctr / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "275997030"
                    }, 
                    "name": "Univ of North Carolina / SOCA"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "9036798", 
            "citation": "Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med. 1997 Feb 15;126(4):264-74."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000799"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hosp / SOCA": "39.29 -76.612", 
        "New York Univ Med Ctr / SOCA": "40.714 -74.006", 
        "Northwestern Univ / SOCA": "41.878 -87.63", 
        "UCLA - Jules Stein Eye Institute / SOCA": "34.052 -118.244", 
        "UCSD - Shiley Eye Ctr / SOCA": "32.839 -117.277", 
        "UCSF - San Francisco Gen Hosp": "37.775 -122.419", 
        "Univ of North Carolina / SOCA": "35.913 -79.056"
    }
}